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DEBATE— The integration of contin-
uous subcutaneous insulin infusion
(CSII) (insulin pump therapy) and con-
tinuous interstitial glucose monitoring
(CGM)appearstobeanexcellentsolution
forobtainingthedesirablemetaboliccon-
trol for most insulin-treated subjects (1–
4). Several studies have suggested that
CGM with readings in real-time (CGM-
RT) further improves blood glucose con-
trol (5–9). The introduction of CGM and
CSII into clinical practice has generated
an inevitable increase in the amount of
datatobemanagedandinterpreted.Tele-
medicinefacilitatesdatamanagementand
preprocessing to optimize therapy.
Amongotherpotentialbeneﬁts,telemedi-
cineimprovescommunicationamongpa-
tientsandhealthcareproviders,improves
quantity and quality of data collection,
and eases decision-making and therapy
adjustment (10–12). DIABTel, a web-
based telemedicine system, is a good ex-
ample for a solution designed to supply
these needs (13).
PARIS (Pa ´ncreas Artiﬁcial Tele-
me ´dico Inteligente) is a coordinated re-
search project to develop and validate a
telemedical artiﬁcial pancreas (TAP), a
multi-access telemedicine system that in-
tegrates CGM-RT, insulin pump, a smart
assistant (SA), and close-loop control al-
gorithms. SA is a personal intelligent as-
sistant based on a handheld digital device
toprovidebothpersonalandremoteloop
strategies, using CGM, CSII, and mobile
general packet radio service (GPRS) com-
munication with a telemedicine central
server (TMCS).
This review summarizes acquired ex-
perienceswithTAP,integratingthesenew
technologies with the objective to im-
prove glycemic control of type 1 diabetic
patients.
RESEARCH DESIGN AND
METHODS
Description of the DIABTel
telemedicine system
The telemedicine architecture consists of
two components: the medical unit (a tele-
medical central server) and the patient
unit (a smart assistant).
The TMCS at the diabetes center of
the hospital continuously runs, receiving
and processing patients’ monitoring data,
messages, and requests for professional
advice.Apreviouspublicationalreadyre-
ported the beneﬁts of DIABTel, allowing
the implementation of an easy-to-use,
user-tailored telemedicine system with a
technological platform allowing tight in-
tegration between multi-access modali-
ties (web, phone, palmtop) for diabetes
management (14).
DIABTel provides the information for
patient management and support for de-
cision-making through the facilities of
four main services: telemonitoring of
main parameters of diabetes care (blood
glucose, diet, insulin doses, physical ac-
tivity, severe hypoglycemia, ketonuria,
sick days), telecare (consultation and su-
pervision), remote information access,
and knowledge management tools. In
previous experiences, DIABTel was effec-
tive, improving patient-doctor interaction,
data display, and patient’s conﬁdence in
self-management by constant professional
supervision (15,16).
The SA supports both personal and
remote-control strategies supervised by
health care professionals through the
TMCS. The transfer of information can be
activated by the patient at any time
through the mobile patient unit, a GPRS-
based SA that supports personal and re-
mote control strategies for patients,
supervised by physicians through the
telemedicine system. The SA architecture
includes functionalities for data manage-
ment: electronic logbook, rule-based rea-
soning methodology in decision support
(17,18),advicegenerationbyrelyingona
diabetic patient simulator, e-mail facility,
andvisualization.Thebloodglucosemea-
surementeditionincludesspeciﬁctimeof
measurement and time intervals between
measurements. Monitoring data stored at
the TMCS can be downloaded to the SA
database through the synchronization
process and vice versa. The multipara-
metric graphic scenario displays a quick
overviewofthepatient’smetabolicstatus,
providing information of interest and
supporting the decision-making process;
variables such as blood glucose, diet, and
administered doses of insulin can be
shown.
SA may also allow communication
with different medical devices (glucose
sensing, insulin pump) for automatic
download.
Operation of TAP
TAP is built in two interlinked loops. The
“personal loop” allows wireless commu-
nication between the SA, the insulin
pump, and the CGM device. The “remote
loop” connects the diabetic subject to the
health care professional via the SA and its
wireless connection to the TMCS. The SA
platform consists of several systems (user
interface,dataaccess,communicationde-
vices, model predictive control, and
TCMS modules) (Fig. 1). The model pre-
dictive control module calculates the
modiﬁcationofthecontinuousinsulinin-
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ing the physiological model of Hovorka
(19) The platform implies two control
modes: 1) the patient decides changes in
the insulin pump program by using the
informationcomingfromtheglucosensor
(free mode), and 2) the patient gets ad-
vice, through the SA, on the insulin bolus
before each meal (advisory mode). The
patientusestheSAtoregisterandtransfer
data related to timing and pre- and post-
prandial glucose levels, amount of in-
gested carbohydrates, and additional
relevantinformation(e.g.,previousphys-
ical exercise). From this information, the
algorithm computes corresponding insu-
lin dose, which has to be approved by the
physician through the Web interface, be-
fore it is shown to the patient. The analy-
sisanddesignisbasedontheMOSAIK-M
(modeling, simulation, and animation of
information and communication systems
in medicine) system model (20). The pa-
tient uses the SA to get results of the pro-
posed insulin bolus and decides to follow
it or not.
The TAP has been evaluated by a re-
search consortium funded by the Euro-
pean Commission: The Intelligent
Control Assistant for Diabetes (INCA
Project), introducing the concept, design,
and preliminary evaluation of a mobile
close-loop system for diabetes manage-
ment. A feasibility pilot was carried out in
a group of type 1 pump-treated diabetic
patients investigated at the Institut fu ¨r
Diabetesforschung (Mu ¨nchen, Ger-
many), with satisfactory outcomes in am-
bulatory scenarios (21).
CLINICAL EVALUATION OF
TAP— Various clinical experiences
havebeendesignedtoinvestigatetheclin-
ical impact of the telemedical artiﬁcial
pancreasin“reallife.”Sofar,tworandom-
izedcrossoverambulatoryclinicalstudies
have been carried out. Clinical study 1
focused to evaluate the results of the orig-
inal web-based telemedicine system.
Clinical study 2 evaluated the impact of
CGM-RT, together with a telemedicine
system.
Clinical study 1: Evaluation of a
telemedicine system that includes
an SA
A comprehensive full description of the
trial is available (22).
Design and methods. The local ethical
committeeapprovedtheprotocolandpa-
tients signed the informed consent. Ten
insulin pump–treated (for more than 1
year) type 1 diabetic subjects (ﬁve
women), mean age 40.6 years (range
21–62 years), diabetes duration 14.7
years (3–52), C-peptide negative, and
A1C 10%, were randomized into inter-
vention versus control groups and
crossed over to alternate arm after 4
weeks. During the intervention phase,
patients were assisted by telemedicine
(DIABTel System). All subjects were in-
structed in the use of the DIABTel web
service, the management of the SA (a
commercial handheld digital assistant;
iPAQHP2210 pocket PC, Palo Alto, CA)
provided with wireless communication
facilities, such as infrared, Bluetooth, and
GPRS. Patients were requested to submit
blood glucose levels directly from a con-
ventional glucose monitor (Accu-Chek,
Accutrend, and Acculink modem; Roche
Diagnostics,Basel,Switzerland)andinsu-
lintreatmentdataatleasttwiceaweek.In
the control phase, patients only used the
conventional glucose monitor plus mo-
dem for sending data, without any feed-
back from the diabetes center. In the
intervention phase, patients were assisted
by telemedicine (DIABTel System) (Fig.
2). Conﬁdentiality was guaranteed
throughdataencryption,usingtheSecure
Locket Layer protocol; patients’ names
were coded when interacting with the
website. The system notiﬁed doctors with
predeﬁned alarm messages for out-of-
range glucose values. After analyzing data
sent by patients, modiﬁcations of insulin
basal rate and boluses were advised when
necessary by heath care professionals; all
exchanged messages were automatically
registered by the DIABTel System. A1C
was measured by ion-exchange high-
pressureliquidchromatography(Bio-Rad
VARIANT II; Bio-Rad laboratories,
Mu ¨nchen, Germany), with a reference
range of 4.2–5.7%. Fructosamine was
measured by a colorimetric assay system
(nitrobluetetrazoliummethod),provided
byBioSystems(Barcelona,Spain);theref-
Figure 1—PARIS Research Project. TAP integrates an SA based on a handheld personal digital
assistant(PDA)toprovidepatientswithclosed-loopcontrolstrategies(personalandremoteloop),
basedonreal-timeCGM,CSII(insulinpump),andamobileGPRS-basedtelecommunication.The
patient decides on the changes in the insulin pump programming, using the information coming
from a glucose sensor. The physician suggests changes in the insulin program, using the informa-
tion provided by the CGM and from the CSII, coming from the personal smart assistant (PSA)
through the TMCS. Close-loop algorithms implemented in the PSA provide a real-time control of
the insulin pump based on glucose sensor data.
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assay coefﬁcient of variation 3% at 281
mol/l and 4% at 531 mol/l). In the
last 72 h of each phase, CGM was per-
formed (CGMS; Minimed Medtronic,
Northridge, CA). A group of variables
were compared (mean glucose, SD, per-
centageoftime180mg/dl,andareaun-
der the curve 180 mg/dl) using data
providedbythesoftwareCGMSensor3.0
(Minimed, Medtronic). SPSS 14 package
for Windows (SPSS, Chicago, IL) was
used for the comparison between groups
(Student’s t for Gaussian distribution,
Mann-Whitney’s U test for non-Gaussian
distribution, for quantitative data; 
2 for
qualitative variables). For comparisons
within a group, Student’s t paired or Wil-
coxon’s test were used. Bivariate correla-
tions between continuous data were
carried out by Spearman’s .
Main results. During the intervention
phase, fructosamine decreased from
393  32 to 366  25 mol/l (P 
0.05), whereas no change was observed
duringthecontrolphase.A1Ctendedto
decrease after the active phase (from
8.0  0.6 to 7.78  0.6%; P  0.073)
but did not change during the control
phase. The number of treatment modi-
ﬁcations prescribed by the physician
and carried out by the patients corre-
lated with the change observed in A1C
during the telecare phase (r  0.729,
P  0.017). Eight of ten patients re-
duced the percentage of home blood
glucose values 180 mg/dl during the
intervention phase, with the total group
mean reduction being 16.6%. The per-
centage of blood glucose values 65
mg/dl was reduced in 29.6%.
Clinical study 2: Evaluation of the
clinical impact of CGM-RT with a
telemedicine system
A comprehensive full description of the
trialisavailable(23).Theaimofthestudy
was to evaluate the impact of the use of
real-time CGM together with a telemedi-
cinesysteminA1Candglucosevariability
in insulin pump–treated type 1 diabetic
patients.
Design and methods. Ten insulin
pump–treated (D-tron plus; Disetronic,
Burgdorf,Switzerland)type1diabeticpa-
tients (ﬁve women), mean age 41.2 years
(range 21–62), duration of diabetes 14.9
years(3–52),wererandomizedinacross-
over study with two phases of 4 weeks’
duration each, with an interim washout
period of 6 weeks. Interaction between
patientsandhealthcareprofessionalswas
supported by the DIABTel System. Real-
time CGM data (Guardian RT, Medtronic
Minimed) was used 3 days per week dur-
ing the experimental phase. A 72-h
masked CGM registry (CGM System
Gold, Medtronic Minimed, Northridge,
CA) was carried out at the end of the con-
trol phase. Monitoring data were re-
trieved directly from the pump, and the
Accutrend glucose monitor (Boehringer
Mannheim, Germany) and Acculink mo-
dem (Roche Diagnostics, Basel, Switzer-
land) were available on the web and the
patient SA (iPAQ HP2210 pocket PC),
which communicates with the DIABTel
server(mobileGPRSWideAreaNetwork)
(Fig.3).Withinthe24-hperiodafterdata
reception, physicians analyzed patients’
data and advised treatment changes,
when necessary. A1C was measured by
ion-exchange high-performance liquid
chromatography (VARIANT II, Bio-Rad),
with a reference range of 4.2–5.7%. Sta-
tistical analyses were performed using
SPSS v 14.0. Comparisons were made us-
ing nonparametric tests for paired data
(Wilcoxon’s test). The study had been
previously approved by the local ethics
Figure2—PARISclinicalstudy1.Themainobjectiveofthestudywastoevaluateclinicalutilities
of the telemedicine system (DIABTel) that includes an SA (iPAQ), provided with wireless com-
municationfacilities.Inthecontrolphase,type1diabeticpatientsdirectlysubmittedbloodglucose
levels from a conventional glucose monitor (Accuchek, Acculink modem) and insulin data to the
diabetes center without any feedback. In the experimental phase, patients were assisted by tele-
medicine (DiabTel) System.
Figure 3—PARIS clinical study 2. The study evaluated the clinical impact of the combined use of
real-timeCGM(GuardianRT)togetherwithtelemedicineininsulinpump–treated(DTRONplus)
type 1 diabetic subjects, integrated in the TAP. Insulin data were retrieved directly from the
DTRON, plus insulin pump real-time CGM was used 3 days per week during the experimental
phase. SMBG was used at all other times during both control and experimental phases. Data were
available on the web and the patient’s SA (iPAQ), which communicated with the DiabTel server.
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formed consent form. To assess glucose
variability, glucose risk index was calcu-
lated to assess glucose variability
(24–27).
Results. The local ethical committee ap-
proved the protocol and patients signed
the informed consent; all patients com-
pleted the study. At the end of the inter-
vention phase, A1C decreased in 9 of 10
patients, with a mean decrease of 0.8%
(8.11.1vs.7.30.8%;P0.007);no
change was observed during the control
phase. The change in A1C observed dur-
ing the intervention phase was higher
than in the control phase (P  0.017).
Data from real-time CGM depicted that
the percentage of glucose values between
70 and 180 mg/dl was higher during the
intervention phase (62 vs. 52%; P 
0.05), without differences in the percent-
ageofvaluesbelow70mg/dl.Theglucose
risk index obtained from the CGM was
higher during the control phase than that
obtained by aggregation of the four mon-
itoring sessions performed during the in-
tervention phase (9.6 vs. 6.25; P  0.05),
which suggests an improvement in glu-
cose stability. The number of insulin bo-
lus doses per day was higher on those
days patients wore the continuous glu-
cose monitor (5.64  1.7 vs. 4.90 
0.96). The DIABTel System was more fre-
quently used during the experimental
phase, particularly logbook visualization
(19.5  9.4 vs. 8.5  4.8 times per pa-
tient per week; P  0.01).
CONCLUSIONS — Self-monitoring
of blood glucose (SMBG) is considered a
standard of care in diabetes management
(28).Aspreviouslydemonstratedfortype
1 diabetes (29–32), the clinical beneﬁt of
SMBG in type 2 diabetes is widely ac-
cepted, with independence from the rec-
ommended type of antidiabetic treatment
(33–37). Responsible use of SMBG re-
quires adequate training and skill perfor-
mance by the patient (38). A1C, SMBG,
meanbloodglucose,andglucosevariabil-
ity measurements should be considered
together,complementingtheinformation
on good and bad control, as well as the
risk for hypoglycemia. Experiences in-
cluding subjects with normal glucose tol-
erance, glucose intolerance, and diabetes,
using SMBG in conjunction with CGM,
investigatedforupto75days,showedthe
same correlations with A1C and glucose
levelvariability(afteraddingtheSDtothe
model). Nevertheless, glucose proﬁles
generated from either SMBG or CGM
showed that identical A1C at different
stratiﬁed levels produced different and
unpredictable diurnal patterns. Although
CGM still remains experimental, it per-
mits recognition of the diurnal modal
proﬁle in ambulatory observation for ex-
tended periods, which may be linked to
diabetes complications (39).
CGM is still a clinically experimental,
invasive (although minimally), rather
cumbersomealternativetoSMBG,requir-
ing the periodic change of the indwelling
sensor(40).Adynamicpictureoftheglu-
cose proﬁle is provided by the CGM, as
well as the direction and speed of its
movement (41). Fasting glucose levels
correlate better with A1C, and it is not a
good indicator of diurnal glucose
changes. In the speciﬁc group of women
with gestational diabetes, in whom post-
prandial glucose is critical regarding fetal
complications, the experience has sug-
gested advantages of CGM in detecting
abnormal postprandial glucose levels
(42).
A recently published multicenter
clinical trial has shown that CGM is asso-
ciated with improved glycemic control in
adults (25 years of age or older) with type
1 diabetes, being the primary outcome of
the change in A1C level at 26 weeks (43).
The same trial, as well as a systematic re-
view and meta-analysis, conﬁrmed that
CGMisnotbetterthanSMBGwithregard
to improvement of metabolic control
among type 1 diabetic children (44). A
plausible explanation for these ﬁndings
may relay in the observation that among
the subjects using CGM, those in the 15-
to 24-year-old group were less adherent
to sensor use than were older or younger
patients(43).Ratesofhypoglycemiawere
similar with CGM and SMBG in all
age-groups.
Our work strongly suggests that the
intermittent use (42% of the time) of
GCM, with the support of telemedicine,
achieves reduction of A1C and improve-
mentofglucosestabilityintype1diabetic
patients. Furthermore, for the ﬁrst time,
real-time CGM, in conjunction with tele-
medical support, has been successfully
assessed. CGM, together with SMBG and
insulin pump, generate a tremendous
amount of data, which makes processing
by patients and physicians quite trouble-
some; thanks to DIABTel, the analysis is
facilitated by data aggregation, statistics,
and graphic registries in an easily inte-
grated and user-friendly manner.
Improved accuracy of real-time CGM
facilitates the development of close-loop
systems,withthegreatestpotentialforthe
near future and the support of the Juve-
nile Diabetes Research Artiﬁcial Pancreas
Project (45).
In conclusion, the PARIS Research
Project has shown that a Telemedicine
System incorporating an SA improves
glucose control in adult type 1 diabetic
subjects. The investigation has also
proven that the use of real-time CGM in
conjunction with telemedical assistance
improvesglucosecontrolandglucosesta-
bility in adult type 1 diabetic patients,
treated with an insulin pump. Because of
the small size of the recruited samples,
these results need to be reproduced in
largergroupsoftype1diabeticpatientsin
the coming future. The Telemedical Arti-
ﬁcial Pancreas solution, proposed in the
PARIS Research Project, integrates a per-
sonal loop that allows wireless communi-
cationbetweentheSA,insulinpump,and
CGMdevice,witharemoteloopthatcon-
nects the diabetic patient to the health
care professional via the SA and its wire-
less communication with a telemedicine
centralserver.TheTAPoffersfourcontrol
strategies, each of them supported by a
special function of the smart assistant. In
strategy 1, the patient decides changes in
theinsulinprogrambyusingtheinforma-
tion provided by the glucose sensor. In
strategy 2, the physician prescribes
changes in insulin treatment, using the
information provided by CGM and CSII,
reaching the TMCS from the SA. In strat-
egy 3, the SA is remotely programmed by
automatic procedure, under the physi-
cian supervision (remote loop control al-
gorithm). Finally, in strategy 4, the SA
provides a real-time control of the insulin
pump based on the information offered
by the CGM (personal loop control algo-
rithm). The selection of a speciﬁc strategy
or combination of strategies depends on
the different circumstances of the patient
(for example, an automatic personal loop
control algorithm could be active at night
and a control mode could be used during
the day). Close-loop systems may gener-
ate a revolution in diabetes management;
nevertheless, their introduction must be
gradual and progressive, in parallel to ad-
vance of knowledge, increasing experi-
ence,accuracyofthesystems,andoverall,
the patient’s safety.
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